B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has reiterated its Buy rating on Novavax (NASDAQ:NVAX) but lowered the price target from $25 to $23.
August 12, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B. Riley Securities has reiterated its Buy rating on Novavax but lowered the price target from $25 to $23.
The reiteration of the Buy rating is positive, but the lowered price target may temper investor enthusiasm. Overall, the impact is neutral as the positive and negative aspects balance each other out.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100